• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Myovant and Pfizer’s path to securing a second nod for Myfembree gets hazy — and investors...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 12, 2022 at 11:02: AM
via Myovant was on tap for a May 6 decision on a supplemental NDA for its three-in-one pill Myfembree, aiming to treat moderate to severe pain associated with endometriosis. With an FDA nod, Myovant would get a $100 million regulatory milestone from partner Pfizer.

article source
 




Top Bottom
Back
Quote